1244.HK
Price:
$3.48
Market Cap:
$802.22M
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative denta...[Read more]
Industry
Biotechnology
IPO Date
2022-12-15
Stock Exchange
HKSE
Ticker
1244.HK
According to 3D Medicines Inc.’s latest financial reports and current stock price. The company's current ROE is -22.37%. This represents a change of 301.47% compared to the average of -5.57% of the last 4 quarters.
The mean historical ROE of 3D Medicines Inc. over the last ten years is -14.76%. The current -22.37% ROE has changed 51.59% with respect to the historical average. Over the past ten years (40 quarters), 1244.HK's ROE was at its highest in in the September 2024 quarter at -5.04%. The ROE was at its lowest in in the September 2022 quarter at -37.96%.
Average
-14.76%
Median
-23.27%
Minimum
-108.63%
Maximum
64.08%
Discovering the peaks and valleys of 3D Medicines Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 28.06%
Maximum Annual ROE = 64.08%
Minimum Annual Increase = -269.52%
Minimum Annual ROE = -108.63%
Year | ROE | Change |
---|---|---|
2024 | -23.27% | -58.46% |
2023 | -56.01% | -48.44% |
2022 | -108.63% | -269.52% |
2021 | 64.08% | 28.06% |
The current ROE of 3D Medicines Inc. (1244.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-62.64%
5-year avg
-14.76%
10-year avg
-14.76%
3D Medicines Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 3D Medicines Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 3D Medicines Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is 3D Medicines Inc.'s ROE?
How is the ROE calculated for 3D Medicines Inc. (1244.HK)?
What is the highest ROE for 3D Medicines Inc. (1244.HK)?
What is the 3-year average ROE for 3D Medicines Inc. (1244.HK)?
What is the 5-year average ROE for 3D Medicines Inc. (1244.HK)?
How does the current ROE for 3D Medicines Inc. (1244.HK) compare to its historical average?